Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with EGFR-TKI in EGFR-positive advanced NSCLC (real-world observational study)
ChiCTR2000038960Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and gefitinib in non-small cell lung cancer (NSCLC), sponsored by Shanxi Cancer Hospital. Primary endpoint: progression-free survival. Started Oct 2020; status: recruiting.
02
Drugs
Rivoceranibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000038960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038960.